Business
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments. “We were excited to enroll the first patient in our registrational IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regu
About this update from Inhibikase Therapeutics, Inc.
[{"type":"image","alt":"Inhibikase Therapeutics","displaySize":"","headline":null,"caption":"Inhibikase Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jrx7oJ.q30fX7LRFGfs16Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52","width":300,"height":136},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Jrx7oJ.q30fX7LRFGfs16Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52","width":300,"height":136}},"lazy":false},{"type":"text","content":"WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments.","length":335,"tagName":"p"},{"type":"text","content":"“We were excited to enroll the first patient in our registrational IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites, including being one of the first companies to successfully take advantage of the new European Medicines Agency FAST-EU (Facilitating and Accelerating Strategic Trials in the European Union) initiative to accelerate multinational clinical trials,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “With the recent approvals obtained in the first 16 countries worldwide, Inhibikase is well-positioned to initiate clinical site activations and seek to advance enrollment of IMPROVE-PAH. Later this week, we also look forward to the first of two new presentations of Phase 1 and pre-clinical studies of IKT-001 at the American Thoracic Society International Conference, to be held in Orlando, Florida.”","length":940,"tagName":"p"},{"type":"text","content":"Recent Developments","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In late April 2026, Inhibikase received confirmation from the European Medicines Agency that the Company i...